Inebilizumab for pediatric IgG4-related disease
Treatments studied
Part of Immune system & allergy clinical trials.
This study tests a drug called inebilizumab in children and teens with IgG4-related disease, a rare condition causing swelling and organ damage. The drug may help reduce the immune system attack that causes the disease. It may be an option if standard treatments haven't fully worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 2 and 17 years old and weigh at least 17 kg (about 37 lbs).
- You must have a diagnosis of IgG4-related disease that meets specific criteria set by the study doctors.
- You must be able to have all required vaccinations before starting the study.
- If you are on steroids for the disease, the dose must be stable for at least 2 weeks before starting the study drug.
- You must not have certain infections, immune problems, or have recently taken medications that could interfere with the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called rilzabrutinib to see if it can safely control IgG4-related disease (a condition causing inflammation in various organs) better than a placebo. It may help you reduce or stop your current steroid treatment.
This study looks at a specific immune signal (C5a) in people with IgG4-related disease to see if it could be a target for future treatments. It compares patients with active disease, those in remission, and healthy volunteers to understand how this signal changes.
This trial tests whether a medication called lenalidomide helps keep your IgG4-related disease in remission and prevents it from coming back. It is for people whose disease is well controlled on low-dose steroids.
This study tests a new drug called inebilizumab for children with generalized myasthenia gravis (gMG), a condition causing muscle weakness. The drug aims to reduce the immune system's attack on nerves, which may improve symptoms. The study will check how safe and effective it is for young patients.
This study tests an investigational drug, ACE1831, in people with active IgG4-related disease (IgG4-RD), a condition where the immune system causes inflammation and swelling in organs. The purpose is to see if ACE1831 is safe and effective in reducing disease flare-ups, possibly offering a new treatment option.
This trial tests a new treatment called BCT301 for people with IgG4-related disease (an autoimmune condition causing swelling in organs like the pancreas or kidneys) that has not improved with standard treatments. The therapy targets certain immune cells to help reduce disease activity.
Hear when a new Immunoglobulin G4-Related Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.